WallStreetZenWallStreetZen

NASDAQ: AKRO
Akero Therapeutics Inc Stock Ownership - Who owns Akero Therapeutics?

OverviewForecastEarningsRevenueDividendOwnership

Insider buying vs selling

Have Akero Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Catriona YaleChief Development Officer2025-03-1710,000$21.10
$211.00kBuy
Catriona YaleChief Development Officer2025-03-171,799$45.05
$81.04kSell
Catriona YaleChief Development Officer2025-03-178,201$44.70
$366.56kSell
Jonathan YoungChief Operating Officer2025-03-12607$44.88
$27.24kSell
Timothy RolphChief Scientific Officer2025-03-12516$44.88
$23.16kSell
William Richard WhiteChief Financial Officer2025-03-12676$44.88
$30.34kSell
Andrew ChengPresident and CEO2025-03-121,738$44.88
$78.00kSell
Catriona YaleChief Development Officer2025-03-12614$44.88
$27.56kSell
Andrew ChengPresident and CEO2025-03-1028,784$41.75
$1.20MSell
Andrew ChengPresident and CEO2025-03-101,216$42.31
$51.45kSell

1 of 17

AKRO insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when AKRO insiders and whales buy or sell their stock.

AKRO Shareholders

What type of owners hold Akero Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Wellington Management Group LLP9.27%7,376,961$332.55MInstitution
Rtw Investments LP8.62%6,859,823$309.24MInstitution
Versant Venture Capital VI LP8.48%6,749,283$304.26MInsider
Janus Henderson Group PLC7.58%6,034,239$272.02MInstitution
Blackrock Inc7.44%5,924,183$267.06MInstitution
Apple Tree Partners IV LP7.32%5,830,203$262.83MInsider
General Atlantic LP6.57%5,233,989$235.95MInstitution
Price T Rowe Associates Inc5.43%4,321,972$194.83MInstitution
Aaron Royston4.97%3,954,858$178.28MInsider
Vanguard Group Inc4.65%3,704,411$166.99MInstitution

1 of 3

AKRO vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
AKRO71.51%28.49%Net BuyingNet Buying
RARE84.55%15.45%Net SellingNet Selling
SWTX65.47%34.53%Net SellingNet Selling
CRSP65.93%34.07%Net SellingNet Selling
ZLAB5.21%1.75%Net SellingNet Selling
View Top Biotech Stocks

Akero Therapeutics Stock Ownership FAQ

Who owns Akero Therapeutics?

Akero Therapeutics (NASDAQ: AKRO) is owned by 93.15% institutional shareholders, 37.11% Akero Therapeutics insiders, and 0.00% retail investors. Versant Venture Capital VI LP is the largest individual Akero Therapeutics shareholder, owning 6.75M shares representing 8.48% of the company. Versant Venture Capital VI LP's Akero Therapeutics shares are currently valued at $305.34M.

If you're new to stock investing, here's how to buy Akero Therapeutics stock.
©2025 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.